272104-64-0Relevant articles and documents
Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4
Cheung, Mui,Bao, Weike,Behm, David J.,Brooks, Carl A.,Bury, Michael J.,Dowdell, Sarah E.,Eidam, Hilary S.,Fox, Ryan M.,Goodman, Krista B.,Holt, Dennis A.,Lee, Dennis,Roethke, Theresa J.,Willette, Robert N.,Xu, Xiaoping,Ye, Guosen,Thorneloe, Kevin S.
, p. 549 - 554 (2017/05/19)
Transient Receptor Potential Vanilloid 4 (TRPV4) is a member of the Transient Receptor Potential (TRP) superfamily of cation channels. TRPV4 is expressed in the vascular endothelium in the lung and regulates the integrity of the alveolar septal barrier. Increased pulmonary vascular pressure evokes TRPV4-dependent pulmonary edema, and therefore, inhibition of TRPV4 represents a novel approach for the treatment of pulmonary edema associated with conditions such as congestive heart failure. Herein we report the discovery of an orally active, potent, and selective TRPV4 blocker, 3-(1,4′-bipiperidin-1′-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide (GSK2193874, 28) after addressing an unexpected off-target cardiovascular liability observed from in vivo studies. GSK2193874 is a selective tool for elucidating TRPV4 biology both in vitro and in vivo.
Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
-
, (2008/06/13)
Certain compounds of formula (I) below or a pharmaceutically acceptable salt or hydrate thereof: (I) wherein: R1 is H or C1-6 alkyl; R2 is aryl or C3-7 cycloalkyl or heteroaryl; R3 is H or C1-3
Quinoline derivatives as NK-2 and NK-3 receptor ligands
-
, (2008/06/13)
A compound, or a solvate or a salt thereof, of formula (I): wherein R is linear or branched alkyl; R1represents hydrogen or up to four optional substituents selected from the list consisting of: C1-6alkyl, C1-6alkenyl, ary